Skip to content

Foundayo in the UAE: What Is It, Who Can Get It, and How to Prescribe or Import It Legally


Foundayo UAE - Hawkridge Corp

The UAE has joined a very short list of countries that have approved Foundayo and it happened fast. Less than 48 hours after the US FDA gave the green light, the Emirates Drug Establishment confirmed its own approval, making the UAE the second country in the world to register this treatment.

For patients, the question is straightforward: am I eligible, and where do I get it? For healthcare providers and pharmaceutical businesses, the questions are more technical: who can prescribe it, how is it dispensed, and what does UAE drug registration require for a product like this?

This guide answers all of it clearly, practically, and from a UAE regulatory standpoint.

What Is Foundayo?

Foundayo (orforglipron) is a once-daily oral weight loss pill developed by Eli Lilly. It belongs to the GLP-1 receptor agonist class, the same family of medicines as Ozempic, Wegovy, and Mounjaro but it is structurally different in one important way.

Most GLP-1 medications are peptide-based molecules. Because peptides are broken down by digestive enzymes, they must be injected. Foundayo is a small-molecule, non-peptide compound, which means it survives digestion and can be reliably absorbed when swallowed as a tablet.

The practical result: Foundayo is the first GLP-1 weight loss treatment that can be taken as a pill, once daily, at any time of day, with or without food or water restrictions. No injections. No needles. No refrigeration. No complex timing requirements.

How Effective Is Foundayo?

The endorsement of Foundayo is based on evidence drawn from a 72-week Phase 3 ATTAIN-1 clinical trial conducted among adults suffering from obesity or being overweight without diabetes.. At the highest approved dose of 17.2 mg, participants lost an average of approximately 12.4% of their starting body weight around 12.3 kg on average compared to under 1% in the placebo group.

Most participants began to see results within four weeks of starting treatment. The full dose is reached gradually through a structured titration schedule, starting at 0.8 mg and increasing in steps to reduce the risk of gastrointestinal side effects early in treatment.

Foundayo UAE: The Regulatory Approval

The Emirates Drug Establishment (EDE) approved Foundayo on 3 April 2026 two days after the FDA’s US approval. This places the UAE among the world’s fastest adopters of innovative pharmaceutical therapies, and reflects the EDE’s priority focus on treatments targeting obesity, which is associated with more than 200 diseases and health complications including type 2 diabetes, hypertension, and at least 13 different types of cancer.

Foundayo UAE availability rolled out across UAE pharmacies from May 2026. It is currently available in Dubai, Abu Dhabi, and Sharjah through MOHAP-licensed pharmacies, and is dispensed only against a valid prescription from a licensed UAE physician.

Abu Dhabi: Government Programme Access

Abu Dhabi took an additional step in April 2026, incorporating Foundayo into the government’s Personalised Weight Management Programme, run in collaboration with the Abu Dhabi Public Health Centre and delivered through the Imperial College London Diabetes and Endocrine Centre. Residents of Abu Dhabi who are eligible for this program will be able to use Foundayo in its entirety under the weight management program, which combines medicine and digital monitoring.

Eligibility for Foundayo in UAE

Foundayo is a prescription-only medicine. It is not available for general sale, and it is not approved for cosmetic weight loss or short-term use. Eligibility is assessed by a licensed physician and follows clinical criteria that are consistent with the UAE EDE approval and the ATTAIN trial population:

Eligibility Criteria

  • BMI of 30 or above (classified as obese), regardless of whether other health conditions are present
  • BMI of 27 or above (classified as overweight) with at least one weight-related medical condition such as type 2 diabetes, hypertension, high cholesterol (dyslipidaemia), obstructive sleep apnoea, or cardiovascular disease

Foundayo is approved for adults only. It is not approved for use in children or adolescents. Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not take Foundayo, as the medication carries a boxed warning relating to the risk of thyroid tumours.

Who Prescribes Foundayo in the UAE?

The UAE physicians confirm that Foundayo should be prescribed by an endocrinologist or an obesity specialist. While a general practitioner may prescribe this medication, at least initial assessment and prescribing by a specialist is highly recommended due to the necessity to carry out proper clinical testing, baseline blood work, and follow-up monitoring.

Prior to taking Foundayo, medical tests are carried out in order to check thyroid function, fasting blood glucose, renal function, and cholesterol levels.

Is Foundayo Covered by Health Insurance in the UAE?

Foundayo is categorized as a prescription weight loss medicine. It will be helpful for the patient to find out from their health insurance provider whether they cover Foundayo prescriptions in the UAE as the treatment has to be taken continuously.

How Foundayo Compares to Other GLP-1 Treatments Available in the UAE

FoundayoMounjaro / ZepboundOzempic / Wegovy
FormatDaily oral pillWeekly injectionWeekly injection
Active ingredientOrforglipronTirzepatideSemaglutide
Food restrictionsNoneNoneNone for injection
Average weight loss (trial)~12.4% at 72 weeksUp to 22.5% at 72 weeks~15% at 68 weeks
UAE approvalEDE-approved April 2026EDE-approvedEDE-approved
Prescription requiredYesYesYes

UAE physicians note that injectable GLP-1 therapies still demonstrate greater average weight loss in clinical trials. Foundayo’s primary advantage is its format for patients who are unwilling or unable to self-inject, Foundayo provides a regulated, effective oral alternative. It is not a replacement for injectable therapies across the board; it is an additional option that widens access and improves adherence for a significant group of patients.

For Pharmaceutical and Healthcare Businesses: Importing or Distributing Foundayo in the UAE

Foundayo is currently distributed in the UAE through Eli Lilly’s established UAE operations under the EDE marketing authorisation. For pharmaceutical companies, distributors, or healthcare providers looking to understand the UAE regulatory framework for a product like Foundayo or for similar obesity medicines seeking UAE market entry the following framework applies.

EDE Registration Is Mandatory

Under Federal Decree-Law No. 38 of 2024, the Emirates Drug Establishment (EDE) is the federal authority responsible for all pharmaceutical marketing authorisations in the UAE. No pharmaceutical product may be imported, marketed, sold, or distributed in the UAE without prior EDE registration. This replaced the former MOHAP drug registration function, effective from 29 December 2025.

Requirements for Importing and Registration of Pharmaceuticals

  • License of the local agent: The applicant (Marketing Authorization Holder) should have an established license to conduct operations via a licensed local agent, which can be either a pharmaceutical manufacturing company, marketing office, or licensed medical warehouse.
  • Complete CTD/eCTD dossier: A full technical dossier needs to be provided in eCTD format, containing information on clinical data, pharmacovigilance data, GMP certificate, and Arabic/English labels.
  • Reference pathway: Approved products by regulatory agencies such as the FDA or EMA can take a verification pathway that substantially reduces the 9-18 months required under the normal review process.
  • Pricing approval: The product is then submitted to the pricing committee of EDE for its pricing process.
  • Ongoing pharmacovigilance: This requirement holds true even after approval through the life-cycle of the product.

Healthcare providers wishing to prescribe or stock Foundayo UAE must obtain it through authorised licensed pharmaceutical channels. Obtaining products through unregistered import routes is a violation of UAE drug law and carries penalties including seizure, fines, and facility licence consequences.

How Hawkridge Corp Can Help

Whether you are a pharmaceutical manufacturer seeking EDE registration for a GLP-1 or obesity medicine, a healthcare provider navigating import and dispensing requirements for Foundayo UAE, or a distributor exploring market entry for a product in this category the regulatory pathway is the same, and getting it right from the start is essential.

At Hawkridge Corp, we work with pharmaceutical companies, importers, and healthcare businesses to manage the full EDE registration and import compliance process from dossier preparation and local entity structuring to pricing submissions and post-approval lifecycle management.

If you are bringing a product like Foundayo to the UAE market, or you are looking to understand how the current EDE framework applies to your pharmaceutical business, our team provides clear, practical regulatory guidance at every step. Contact Hawkridge Corp today to discuss your pharmaceutical registration and import compliance needs in the UAE.

Final Thoughts

Foundayo marks a genuine shift in how obesity is treated moving from weekly injections to a daily oral pill with no food or timing restrictions. The UAE’s rapid EDE approval, making it only the second country in the world to register the treatment, reflects both the scale of the obesity challenge in the region and the EDE’s commitment to fast-tracking access to pharmaceutical innovation.

For patients: Foundayo UAE is available now, by prescription, for eligible adults. For pharmaceutical and healthcare businesses: the regulatory pathway for obesity medicines and GLP-1 therapies in the UAE is now centralised entirely through the EDE, and compliance from day one is non-negotiable.